Viatris Greater China — Cost of Sales increased by 14.5% to $70.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.6%, from $60.80M to $70.90M. Over 3 years (FY 2022 to FY 2025), Greater China — Cost of Sales shows an upward trend with a 8.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to sales suggests margin compression due to rising input costs or pricing pressures.
The direct costs attributable to the production and distribution of pharmaceutical products sold within the Greater Chin...
Standard cost of goods sold (COGS) metric for regional segments in the pharmaceutical industry.
vtrs_segment_greater_china_cost_of_sales| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.95M | $48.95M | $48.95M | $48.95M | $51.38M | $51.38M | $51.38M | $51.38M | $61.20M | $59.20M | $65.30M | $60.00M | $60.80M | $62.50M | $65.40M | $61.90M | $70.90M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +5.0% | +0.0% | +0.0% | +0.0% | +19.1% | -3.3% | +10.3% | -8.1% | +1.3% | +2.8% | +4.6% | -5.4% | +14.5% |
| YoY Change | — | — | — | — | +5.0% | +5.0% | +5.0% | +5.0% | +19.1% | +15.2% | +27.1% | +16.8% | -0.7% | +5.6% | +0.2% | +3.2% | +16.6% |